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Paolo Bruzzi, MD,b and Beatrice Dozin, PhDb
Objective: The role of surgery in the treatment of preoperatively diagnosed N2 non–small cell lung cancer re-
mains controversial. This study sought significant prognostic factors to select candidates for surgery and assess
prognosis.
Methods: The study population included 277 patients who underwent primary resection (192) or induction che-
motherapy followed by surgery (85) for preoperatively diagnosed, potentially resectable N2 non–small cell lung
cancer. N2 descriptors were prospectively recorded. Kaplan–Meier curves were used to evaluate survival, and
statistical significance of differences between curves was assessed by log-rank test. Cox regression was used
for multivariate analyses.
Results: Preoperative significant prognostic factors were number of mediastinal node levels involved (P<.001),
symptom severity (P ¼ .013), clinical T (P ¼ .041), and induction chemotherapy (P ¼ .001). Three groups with
different prognoses were based on individual prognostic score. The group that did best had a median survival of
29.6 months. Postoperative predictors of survival were pathologic T (P ¼ .003), tumor residue (P ¼ .034), and
number of mediastinal nodes involved (P< .001). Of 3 groups with different prognoses, the most favorable had
a median survival as long as 42 months.
Conclusion: This study provides a practical tool that uses significant prognostic factors to predict which patients
with preoperatively diagnosed N2 non–small cell lung cancer have better prognoses. Because patients with the
favorable prognostic factors showed good long-term survival and excellent local disease control, surgery should
still play an important role in the multimodality treatment of these patients.Earn CME credits at
http://cme.ctsnetjournals.org
The role of surgery in the treatment of patients with N2 non–
small cell lung cancer (NSCLC) has been repeatedly investi-
gated during the last decades. Patients with N2 NSCLC repre-
sent an heterogeneous category that includes subsets with
different prognoses and treatment options.1 Few patients with
N2 NSCLC are candidates for curative surgery, and those
with preoperative diagnoses appear to have a significantly
worse prognosis than those whose N2 disease is diagnosed in-
traoperatively.2 Controversy persists regarding which patients
with preoperatively diagnosed N2 NSCLC are candidates for
surgery.2 Two recent randomized trials investigated the poten-
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of preoperatively diagnosed N2 NSCLC (Radio Therapy On-
cology Group [RTOG] 93093; European Organization for Re-
search and Treatment of Cancer [EORTC] 089414). The first
trial (RTOG 9309) addressed this issue in patients with techni-
cally resectable N2. Although that trial showed an increased
treatment-related mortality in the surgical arm and no signifi-
cant difference in overall survival between the two arms, a sig-
nificant improvement in disease-free survival was observed in
the surgical arm. The second trial (EORTC 08941) investigated
the role of surgery in patients with N2 NSCLC initially judged
to be unresectable. Surgery improved neither overall nor dis-
ease-free survival, and in the surgical arm, about half of the pa-
tients received useless surgery (exploratory thoracotomy or
incomplete resection). Furthermore, most patients who did
have resection underwent pneumonectomy, suggesting that
bronchoplastic and angioplastic techniques were not widely
adopted. One might also argue that the disappointing results
of the EORTC trial were related to the selection criteria and
to the large number of participating centers.
To assess the potential and limits of surgery in preopera-
tively diagnosed N2 NSCLC, we analyzed 277 consecutive
patients who underwent resection by a single surgical team.
Preoperative and postoperative prognostic parameters were
prospectively collected. The study was designed to record
N2 descriptors for every patient and to assess survival
according to these prognostic factors. Another aim was toardiovascular Surgery c Volume 138, Number 4 849
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CT ¼ computed tomograpy
MLND ¼ mediastinal lymph node dissection
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
develop two risk scores, one based on preoperative descrip-
tors to avoid selecting patients unsuitable for resection and
the other based on postoperative prognostic factors to predict
outcome after resection.
MATERIALS AND METHODS
This study included 277 consecutive patients with preoperatively docu-
mented N2 NSCLC who underwent resection and systematic mediastinal
lymph node dissection (MLND) between February 1991 and July 2004.
All data were prospectively collected. One hundred ninety-two patients
were treated with initial surgery and 85 with induction chemotherapy fol-
lowed by surgery (Figure 1). Before induction chemotherapy became the
standard treatment for N2 NSCLC in our institution, surgery was the initial
treatment. By 1999, induction chemotherapy became our first option, and
only patients who refused induction chemotherapy were treated primarily
with surgery. The N2 status was preoperatively determined by computed
tomography (CT) scan (mediastinal nodes with the shorter diameter of 10
mm or more were considered potentially metastatic) and confirmed by
cervical mediastinoscopy or left anterior mediastinotomy, depending on
the location of enlarged nodes. Every patient with left-sided NSCLC and
a positive left anterior mediastinotomy result underwent cervical mediasti-
noscopy, regardless of the size of paratracheal and pretracheal nodes.
Patients with no sign of enlarged mediastinal nodes on CT scan and those
with a negative mediastinoscopy result who had restaging to N2 during sur-
gery were not included in the study. Patients with bulky mediastinal nodes
(defined as nodes with the shorter diameter larger than 20 mm) were not
excluded from the study if resection completeness was expected. Both in
the primary surgery period and in the induction chemotherapy period,
patients with mediastinoscopic evidence of extranodular tumor spread pre-
cluding resectability were denied surgery. Six patients who died within
30 days after surgery were included in the analysis.
The study was approved by the ethical committee of the Institute and con-
ducted in accordance with the International Good Clinical Practice Guidelines.
All patients were aware of the aims and procedures of the study, and all signed
an informed consent for participating in the study before undergoing induction
chemotherapy or before surgery if no induction therapy was used.
Inclusion Criteria
Inclusion criteria were as follows: (1) preoperative histologic diagnosis
of N2 NSCLC by either cervical mediastinoscopy or anterior mediastinot-
omy; (2) feasibility of achieving complete resection; (3) performance status
of 0 or 1; (4) compatible cardiorespiratory function; and (5) no N3 disease,
distant metastases, malignant pleural effusion, or vena cava syndrome.
Pretreatment Staging
Patients with N2 NSCLC, who are at high risk, underwent an extensive pre-
operative staging, including the following: chest roentgenography; CT of the
brain, chest, and upper abdomen; ultrasonography of the upper abdomen when
indicated; magnetic resonance imaging of the brain when indicated on the ba-
sis of CT scan findings, bone scan; from 2002 on, positron emission tomog-
raphy (PET) scan (in these cases, bone scan was avoided); bronchoscopy;
and mediastinoscopy. After the introduction of PET scanning, patients with850 The Journal of Thoracic and Cardiovascular Surpositive mediastinal nodes on PET scan (regardless of the diameter of medi-
astinal nodes on CT scan) and those with enlarged mediastinal nodes on CT
scan (regardless of PET scan findings) underwent mediastinoscopy.
Preoperative Functional Evaluation
Pulmonary functional evaluation included blood gas analysis, spirome-
try, and quantitative lung ventilation/perfusion scans (except for patients
with a normal results of spirometry). Determination of the maximum oxy-
gen consumption during exercise was used when predicted postoperative
values of either forced expiratory volume in 1 second or diffusing capacity
for carbon monoxide was lower than 40% predicted. Patients were judged
suitable for resection when maximum oxygen consumption was greater than
15 mL/kg/min. Cardiac risk was assessed by stress echocardiography in pa-
tients with a history of heart symptoms or abnormal electrocardiogram.
Treatment Plan
A platinum-based (80 mg/m2) induction regimen combined with at least
one other drug (gemcitabine, paclitaxel, or vinorelbine) was used. The treat-
ment cycle was repeated two more times at 3-week intervals in patients who
had sufficient recovery from toxic effects of the previous cycle. Because all
patients had disease that was initially judged resectable, neoadjuvant radia-
tion therapy was never used. After induction chemotherapy, all patients
again underwent CT scans of the brain, chest, and upper abdomen, along
with bronchoscopy and functional evaluation. Repeated mediastinoscopy
or endobronchial ultrasonography was not included in this evaluation. Start-
ing from 2002, all patients underwent a PET scan 3 to 4 weeks after the com-
pletion of induction chemotherapy to evaluate the metabolic response to the
induction treatment (standardized uptake values). Patients showing no re-
sponse to the induction treatment or showing severe chemotherapy toxicity
did not undergo surgery and were excluded from the study. Adjuvant radi-
ation therapy to the mediastinum (45–50 Gy) was given to most patients.
Patients with incomplete resections (R1 or R2) received further radiotherapy
to the residual disease (60 Gy).
Surgery
All operations were performed according to the same oncologic and tech-
nical principles. Tumors adhering to the pericardium, thoracic wall, diaphragm,
atrium, or great vessels were approached with en bloc removal of lung and
352 potentially resectable
N2-NSCLC patients
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No
195 patients
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157 patients
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195 patients
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85 patients
No surgery
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277 patients
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FIGURE 1. Algorithm for selection of study patient population. NSCLC,
Non–small cell lung cancer.gery c October 2009
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STABLE 1. Univariate and multivariate analyses: Survival according to preoperative factors
Patients Deaths Univariate Multivariate
Factor No. % No. % Median survival (mo) P value* HR 95% CI P valuey
Sex .8525 RFM .821
Male 229 82.7% 157 63.6% 20.5 — —
Female 48 17.3% 28 58.3% 19.9 — —
Age (y) .3328 RFM .718
<60 74 26.7% 55 74.3% 17.0 — —
60–65 68 24.5% 41 60.3% 22.7 — —
65–70 63 22.7% 46 73.0% 19.9 — —
>70 72 26.0% 43 59.7% 20.0 — —
Performance status
(Eastern Cooperative
Oncology Group)
.2069 RFM .074
0 182 65.7% 121 66.5% 21.2 — —
>0 95 34.3% 64 67.4% 18.5 — —
Symptomsz .0129 .013
None (reference) 63 22.7% 39 61.9% 23.6 1 —
Mild 65 23.5% 41 63.1% 21.2 1.311 0.842–2.042
Moderate 83 30.0% 52 62.7% 20.6 1.116 0.727–1.712
Severe 66 23.8% 53 80.3% 12.8 1.987 1.243–2.896
Clinical T status .0688 TT — .041
T1 34 12.3% 19 55.9% 23.3 — —
T2 159 57.4% 101 63.5% 22.0 — —
T3 67 24.2% 51 76.1% 14.6 — —
T4 17 6.1% 14 82.3% 18.0 1.236 1.011–1.510
Lymph node levels
involved (no.)
<.0001 <.001
1 (reference) 184 66.4% 110 59.8% 22.7 1 —
2 70 25.3% 56 80.0% 16.8 1.744 1.256–2.422
>2 23 8.3% 19 82.6% 11.1 3.109 1.869–5.173
Bulky tumorx .7276 RFM .636
No 247 89.2% 163 66.0% 20.8 — —
Yes 30 10.8% 22 73.3% 17.5 — —
Induction chemotherapy .0012
No (reference) 192 69.3% 143 74.5% 18.7 1 —
Yes 85 30.7% 42 49.4% 27.1 0.543 0.380–0.778 .001
Site of neoplasia .1414 RFM .490
Right 159 118 111 74 18.7 — —
Left 57.4% 42.6% 60.0% 40.0% 21.9 — —
In multivariate Cox model, all variables were initially included in the model. Variables not significantly associated with overall survival (P>.05) were removed from the model by
means of a step-down procedure. HR, Hazard ratio; CI, confidence interval; RFM, removed from final model; TT, test for trend. *By log-rank test. yBy Cox regression (c2).
zSymptoms were graded as follows: mild, cough, asthenia; moderate, exerting dyspnea, fever, blood-tinged or blood-streaked sputum, weight loss less than 5% of body weight;
severe, hemoptysis (defined as whole blood sputum), pain, dyspnea while resting, weight loss more than 5% of body weight. xBulky mediastinal nodes were defined as nodes with
the shorter diameter larger than 20 mm.involved structures. Wedge resections were never performed. Sleeve resections
were preferred to pneumonectomy whenever the completeness of resection
was not jeopardized. Complete MLND was performed in all cases as previ-
ously described.5,6 All nodes encountered were removed from the Naruke
map areas 11, 10, 9, 8, 7, 4, 3, and 2 for tumors of the right side and from
the areas 11, 10, 9, 8, 7, 6, and 5 for those of the left side. Patients were con-
sidered to have complete resection (R0) whenever no gross residual tumor was
left, the margins of the resection were microscopically free of cancer, and no
metastasis was found in the highest lymph node dissected.7 R1 and R2 resec-
tions indicate microscopic and macroscopic residual tumor, respectively.
Follow-up
Follow-up included physical examination, routine blood tests, and chest
radiography every 3 months for the first 2 years, every 6 months during theThe Journal of Thoracic and Cthird year, and once a year thereafter. For most patients, CT scans of the
chest and upper abdomen were done at 12 and 24 postoperative months,
unless a relapse was suspected before.
Statistical Analysis
All eligible patients who underwent resection during the study period
were included in the analysis. The primary end point was overall survival
computed from the date of surgery to the date of last contact or the date
of death from any cause. Kaplan–Meier curves were used to evaluate sur-
vivals of each group, and the statistical significance of differences between
curves was assessed with the log-rank test. All variables used as potential
risk factors are listed in Tables 1 and 2. Cox regression was used for multi-
variate analyses to assess the independent role of each prognostic factorardiovascular Surgery c Volume 138, Number 4 851
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STABLE 2. Univariate and multivariate analyses: Survival according to postoperative factors
Patients Events Univariate Multivariate
Factor No. % No. % Median survival (mo) P value* HR 95% CI P valuey
Surgery .0023 RFM .098
Pneumonectomy 69 24.9% 52 75.4% 13.5 — —
Lobectomy or
bilobectomy
208 75.1% 133 63.9% 22 — —
Histologic type .0103 RFM .102
Squamous
carcinoma
139 50.2% 89 64.0% 22 — —
Adenocarcinoma 115 41.5% 86 74.8% 17.8 — —
Other 23 8.3% 10 43.5% 42.4
Grading categoryz .2557 RFM .735
G0 10 3.6% 4 40.0% 70.2 — —
G1–G2 155 56.0% 110 71.0% 20 — —
G3–G4 112 40.4% 71 63.4% 19.7 — —
pT <.0001 .003
T0 (reference) 10 3.6% 4 40.0% 70.2 1
T1 46 16.6% 23 50.0% 25.4 1.085 0.352–3.349
T2 124 44.8% 77 62.1% 23.6 1.198 0.404–3.552
T3 54 19.5% 40 74.1% 14.5 1.678 0.551–5.113
T4 43 15.5% 41 95.4% 12.4 2.564 0.854–7.699
Tumor size (cm)
0 10 3.6% 4 40.0% 70.2 .9404 NI
>0,<2.5 52 18.8% 33 63.5% 24.6 — —
2.5–3.5 62 22.4% 40 64.5% 19.9 — —
3.5–5.0 87 31.4% 64 73.5% 19.8 — —
>5.0 66 23.8% 44 66.6% 18.6 — —
pN .0006 NI
N0 25 9.0% 6 24.0% 75.1 — —
N1 5 1.8% 0 0% — — —
N2 247 89.2% 179 72.5% 18.9 — —
Lymph nodes involved
(no.)
<.0001 <.001
0 (reference) 30 10.8% 6 20.0% 75.1 1
1–3 105 37.9% 60 57.1% 24.6 2.11 0.856–5.202
4–9 93 33.6% 74 79.6% 16.6 3.446 1.405–8.443
>9 49 17.7% 45 91.8% 12.7 4.83 1.892–12.333
Lymph node levels
involved (no.)
<.0001 RFM .107
0 30 10.8% 6 20.0% 75.1 — —
1 121 43.7% 79 65.3% 23.6 — —
2 76 27.4% 57 75.0% 16.8 — —
>2 50 18.1% 43 86.0% 12.7 — —
Resection completeness <.0001 .034
R0 (reference) 219 79.1% 132 60.3% 23.6 1
R1 44 15.9% 39 88.6% 12.4 1.487 0.998–2.214
R2 14 5.0% 14 100% 8.6 1.954 1.069–3.574
Skip metastasisx .5203 RFM .851
No 215 77.6% 142 66.0% 20.6 — —
Yes 62 22.4% 43 69.4% 18.7 — —
Extranodal spreadx .0001 RFM .341
No 219 79.1% 137 62.6% 22.7 — —
Yes 58 20.9% 48 82.8% 13.0 — —
Bulky mediastinal nodesx .0082 RFM .404
No 240 86.6% 153 63.7% 21.2 — —
Yes 37 13.4% 32 86.5% 12.8 — —852 The Journal of Thoracic and Cardiovascular Surgery c October 2009
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STABLE 2. Continued
Patients Events Univariate Multivariate
Factor No. % No. % Median survival (mo) P value* HR 95% CI P valuey
Adjuvant therapy
None 82 29.6% 47 57.3% 19.9 .9082 RFM .166
Chemotherapy 15 5.4% 12 80.0% 17.8 — —
Radiotherapy 105 39.4% 74 67.9% 21.8 — —
Chemoradiotherapy 71 25.6% 52 73.2% 16.8 — —
In multivariate Cox model, all variables were initially included in the model. Variables not significantly associated with overall survival (P>.05) were removed from the model by
means of a step-down procedure. HR, Hazard ratio; CI, confidence interval; RFM, removed from final model; NI, not included in equation for computational reasons. *By log-rank
test. yBy Cox regression (c2). zGrade was assessed in a double-blinded manner by two experienced pathologists according to the classification of the World Health Organization.
xSkip metastasis was defined as metastasis to mediastinal nodes without involvement of bronchopulmonary nodes; extranodal spread was defined as proliferating tumor cells pres-
ent in perinodal tissue; bulky mediastinal nodes were defined as nodes with the shorter diameter larger than 20 mm.while adjusting for the effects of other factors. Multivariate analyses started
from the full model, with all covariates included, unless indicated otherwise.
Factors not significantly (P > .05) associated with survival were then
removed from the model by means of a step-down procedure that was based
on the likelihood ratio test. Hazard ratios of the variables included in the
final model were obtained by exponentiating the coefficients estimated by
the Cox model. The prognostic profile of each patient was then used to com-
pute an individual risk score on the basis of the coefficients of the prognostic
variables included in the final model. Individual risk scores were computed
by multiplying the hazard ratios associated with the prognostic profile of
each individual, as estimated in Cox regression analyses. Three groups of
risk score—low, medium and high—were established on the basis of the ter-
tiles of individual patient scores. Details on how to compute individual risk
scores are shown in Figure 2. Survivals of the three groups were then eval-
uated. Two different sets of models were fitted. The first model included
only preoperative information, to predict the prognoses of patients with
N2 NSCLC who were candidates for resection. The second included both
preoperative and surgical information, to assess the individual prognosis.
Statistical analyses was carried out with the SPSS package (version 11 for
Windows; SPSS, Inc, Chicago, Ill).
RESULTS
From 1991 to 2004, a total of 352 patients with N2
NSCLC were selected as having technically resectable dis-
ease (Figure 1). Of these, 157 (157/352, 44.6%) received in-
duction chemotherapy and 195 (195/352, 55.4%) did not.
Among the 157 patients who underwent induction chemo-
therapy, 72 (72/157, 45.7%) did not progress to surgery be-
cause of deterioration in overall health status, complications
after chemotherapy, or disease progression. The other 85
patients (85/157, 54.3%) with responses to the treatment
underwent resection. Among the 195 patients who went
straight to surgery, 3 (3/195, 1.5.0%) underwent exploration
only and 192 (192/195, 98.5%) underwent resection. The 3
patients with exploration only were excluded from the anal-
ysis, because only patients with resection were included in
the study population. The rate of complete resection (R0)
was 79% (219/277 patients). An incomplete resection was
performed in 58 cases: R1 in 44 patients (44/277, 15.9%)
and R2 in 14 patients (14/277, 5.1%). Details on patients re-
ceiving induction chemotherapy but not proceeding to sur-
gery have not been provided, because assessing the role of
induction chemotherapy was out of the scope of this study.The Journal of Thoracic and CThe median observation time from surgery to death or
censoring was 16.8 months (range 16 days–116 months).
Ninety-two patients (92/277, 33.2%) were alive at the end
of the follow-up period, with a median follow-up of 30
months (range 7.9–116 months). Eighty-three of these pa-
tients (83/277, 30.0%) were free from relapse. Overall,
185 patients (185/277, 66.8%) died during follow-up. One
hundred fifty-five of these patients died from tumor relapse.
Relapse sites were local (44/277, 15.9%), contralateral lung
(32/277, 11.6%), adrenal gland (5/277, 1.8%), brain (29/
277, 10.5%), skeleton (8/277, 2.9%), and liver (1/277,
0.4%). Recurrences were local and systemic in 8.3% (23/
277) and systemic multiple in 7.9% (22/277,). Thirty pa-
tients died without a diagnosis of tumor relapse. Cumulative
overall survivals at 1, 3, and 5 years in the entire group of
patients were 72.6%, 37.5%, and 21.3%, respectively.
Median overall survival was 16.8 months.
Patient clinical profiles are shown in Table 1. In univariate
analysis, the preoperative factors significantly associated
with survival were the severity of symptoms (P ¼ .0129),
the number of lymph node levels involved (P< .0001),
and induction chemotherapy (P ¼ .0012). An association
of borderline significance (P ¼ .0688) was observed be-
tween T status and survival. Particularly poor survivals
were observed for patients with severe symptoms (median
survival 12.8 months), for patients with T3 (median sur-
vival 14,6 months), and for patients with involvement of
more than 2 lymph node levels (median survival 11.1
months). In multivariate analysis, the following factors
were found to be significant independent predictors of
survival: number of involved nodal stations (P < .001),
severity of symptoms (P ¼ .013), preoperative T status (P
¼ .041), and induction chemotherapy (P ¼ .001). The sur-
vivals of the three risk group of patients, calculated as
described here, are shown in Figure 3. It is interesting to
note that the difference between the best prognosis group
and the intermediate prognosis group started to become no-
ticeable only 2 years after surgery. Overall survivals in the
best prognosis group were 40% and 32% at 5 and 8 years,
respectively. Conversely, overall survival in the worstardiovascular Surgery c Volume 138, Number 4 853
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SPreoperative individual score  =
1.00 if clinical T = 1
1.03 if clinical T = 2
1.58 if clinical T = 3
1.78 if clinical T = 4
1.00 if symptoms = null
1.16 if symptoms = mild
1.30 if symptoms = moderate
1.80 if symptoms = severe
1.00 if number of levels = 1
1.67 if number of levels = 2
3.26 if number of levels  >2
xx
Score ≤ 1.34 = low risk
Score >1.34 - ≤ 2.07 = medium risk
Score >2.07= high risk
Postoperative individual score =
1.00 if pathological T = 0
1.05 if pathological T = 1
1.07 if pathological T = 2 
1.61 if pathological T = 3
2.41 if pathological T = 4 
1.00 if number of nodes = 0
2.72 if number of nodes = 1 to 3
4.63 if number of nodes = 4 to 9
6.16 if number of nodes >9
1.00 if tumor residue = null
1.48 if tumor residue = minimal
2.17 if tumor residue = extended
xx
Score ≤ 2.92 = low risk
Score > 2.92 - ≤ 6.56 = medium risk
Score > 6.56= high risk
FIGURE 2. Equation for individual risk score evaluation. Hazard ratios reported for each prognostic factor are derived from multivariate Cox regression.
Patient individual risk score is determined by multiplying hazard ratios corresponding to diagnosis. Threshold values of risk scores are based on tertiles of
individual patient scores.prognosis group was very poor (22% at 2 years and<10%
at 5 years).
The pathologic and surgical descriptors are listed in Table
2. At surgery, 30 patients (30/277, 10.8%) were found to
have N0 disease at the level of the mediastinum. All these pa-
tients had received induction chemotherapy. Among them,
25 had disease classified as pN0, whereas the remaining 5
had a classification of pN1. In univariate analysis, the factors
significantly associated with survival were as follows: type of
surgery (P¼ .002), histologic type (P¼ .0103), pathologic T
status (P< .0001), N status (P ¼ .0006), number of lymph
nodes involved (P<.0001), number of lymph node stations
involved (P< .0001), incomplete resection (R1–R2, P<
.0001), extranodal metastases (P ¼ .0001), and bulky N2
(P ¼ .0082). A multivariate Cox regression was then per-
formed. It included all the postoperative factors except N
status (TNM classification system), tumor diameter, and
histologic type. The first two factors were omitted because
of collinearity with the number of metastatic lymph nodes
and with the pathologic T status, respectively. Histologic
type was omitted because no difference in survival was
seen between squamous carcinoma and adenocarcinoma,
whereas the number of patients with other tumors was very
small (n ¼ 23), precluding convergence of the statistical
models. The significant predictors of survival were as fol-
lows: pathologic T status (P ¼ .003), incomplete resection
(R1–R2, P ¼ .034), and number of lymph nodes involved
(P< .001). Again, an individual prognostic score was com-
puted, and the survivals of the three groups created are shown
in Figure 4.
A single multivariate analysis combining all the signifi-
cant preoperative and postoperative prognostic factors854 The Journal of Thoracic and Cardiovascular Surshowed that only the three postoperative factors could be
maintained in the final analysis: pathologic T status (P ¼
.002), incomplete resection (R1–R2, P¼ .020), and number
of lymph nodes involved (P< .001). Conversely, all four
preoperative factors were no longer significantly associated
with survival and were removed from the model. Thus the
three significant postoperative factors appear to supplant
completely the prognostic role of the preoperative factors.
The 5-year overall survivals were 47%, 16%, and 5% in
the best, the intermediate, and the worst prognosis groups,
respectively.
DISCUSSION
Although it has been repeatedly stressed that preoperatively
demonstrated N2 disease is one of the most unfavorable prog-
nostic factors in resected NSCLC,1,7-12 controversy still per-
sists as to which factors have greater influence on prognosis
and which treatment option offers the best long-term survival.
This study attempted to answer these questions, although the
selection criteria used here were rather stringent and allowed
us to obtain results that could have been worse if less restrictive
settings had been applied.
Searching for significant prognostic factors in patients
with N2 disease, Martini and colleagues13 and Goldstraw
and associates6 found that patients with the involvement of
a single nodal station did significantly better than did pa-
tients with more stations involved. Suzuki and coworkers14
studied 16 clinical and pathologic factors in 95 patients with
N2 NSCLC who underwent resection. Four negative prog-
nostic factors were identified: clinical N2, incomplete resec-
tion, large tumor size, and multiple station N2 metastases.
Unfortunately, in that study the N2 status was assessedgery c October 2009
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SFIGURE 3. Overall survivals of three patient groups created on basis of tertiles of individual preoperative prognostic scores. Scores were derived from
hazard ratio coefficients estimated by multivariate analysis.only on CT scan imaging, and no mediastinoscopic demon-
stration was provided. Andre and associates1 investigated
702 consecutive patients who underwent surgical resection
at six French institutions. They found four negative prognos-
tic factors: clinical N2, involvement of multiple lymph node
stations, pT3 or pT4, and lack of preoperative chemother-
apy. Ruckdeshel and coworkers15 and Vansteenkiste and
colleagues16 reported that patients with a limited number
of lymph node stations involved at mediastinoscopy could
be considered candidates for surgical resection. Similarly,
Japanese researchers reported a better 5-year survival for pa-
tients with a limited number of N2 nodes involved.13,17,18
When interpreting the influences of all these prognostic fac-
tors on survival, we should consider that their values are re-
lated to a number a variables, including the extent of MLND
and the criteria used for defining potentially resectable N2
disease.
The need for routine MLND, remains controversial in not
only the treatment but also the staging of NSCLC. In a non-
randomized study, Keller and colleagues19 reported thatThe Journal of Thoracic and Csystematic sampling is as useful as MLND in staging of
NSCLC, whereas MLND identifies significantly more sta-
tions of involved N2 nodes. In this study, we assumed
that MLND would be essential for assessment of the prog-
nostic significance of the N2 status predictors. MLND has
also been associated with improved survival in right-sided
but not left-sided NSCLC.19 Differences in lymphatic
drainage patterns and the limited surgical access to paratra-
cheal nodes in the left side of the chest are possible expla-
nations. In this study, in which the mediastinum was
extensively investigated before surgery, there was no signif-
icant difference in survival between right-sided and left-
sided tumors.
Although the criteria for defining potentially resectable
N2 disease remain highly subjective, we have attempted to
standardize the selection of patients with N2 NSCLC by us-
ing (1) uniform staging and inclusion criteria, except for the
introduction of PET scan during the last years; (2) routine
mediastinoscopy; and (3) mediastinoscopic detection of
unsuspected paratracheal metastatic nodes in patients withFIGURE 4. Overall survivals of three patient groups created on basis of tertiles of individual postoperative prognostic scores. Scores were derived from
hazard ratio coefficients estimated by multivariate analysis.ardiovascular Surgery c Volume 138, Number 4 855
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With regard to mediastinal node staging, the introduction of
PET scan did not significantly change the diagnostic
approach throughout the study; only 2 patients with medias-
tinal nodes less than 10 mm had a positive PET scan of the
mediastinum.
This study shows that the group of patients with preoper-
atively diagnosed N2 NSCLC is indeed heterogeneous, and
that three subgroups of patients with different prognoses
can be identified according to significant prognostic factors
(severity of symptoms, clinical T status, number of medias-
tinal nodal levels involved, and induction chemotherapy).
Interestingly, in a group with otherwise poor prognosis,
a subset of patients with a median survival of 29.6 months
could be distinguished preoperatively. When postoperative
significant factors (pathologic T status, number of lymph
nodes involved, and complete surgical resection) are con-
sidered, the clinical N2 NSCLC group can be divided into
three other subsets with different prognoses, among which
the most favorable showed a median survival as long as
42 months.
The multivariate analyses also indicated that bulky N2
and extracapsular spread were not significant prognostic fac-
tors in this series. This is probably because most patients
with bulky N2 or extracapsular spread at mediastinoscopy
were considered to have unresectable disease and were
therefore excluded from the study. As a consequence, the pa-
tients with bulky mediastinal nodes or extracapsular nodal
disease included in our study represent a highly selected sub-
group. Our results thus do not apply to the general popula-
tion of patients with bulky N2 or extracapsular spread.
Few reports in literature have dealt with the prognostic
significance of skip metastases. Prenzel and colleagues20 re-
ported a 5-year survival of 41% for patients with pN2 skip
metastases, in contrast to 14% for patients with both N1
and N2 metastatic nodes. In our series, skip N2 metastases
did not predict a better long-term survival.
The prognostic significance of the site of mediastinal no-
des involved has already been investigated. A significantly
worse prognosis has been reported for patients with metasta-
ses to subcarinal nodes.21,22 Goldstraw and associates6
found that metastases in subcarinal nodes had no adverse in-
fluence on survival. In our study, subcarinal node involve-
ment was not associated with a worse prognosis. This may
depend on the extensive preoperative staging of the medias-
tinum and routine MLND.
The recently published American College of Chest Physi-
cians guidelines for patients with preoperatively identified
N2 disease recommend chemoradiation as the standard ther-
apy, with surgery considered after induction chemotherapy
in the settings of a clinical trial.2 This study suggests that
there are subsets of patients with preoperatively diagnosed
N2 NSCLC who might benefit from a surgical approach.
We are aware that our findings must be validated in further856 The Journal of Thoracic and Cardiovascular Surtrials involving large series of patients before introducing
them into clinical practice. Once validated, the prognostic
algorithms developed in this study (see Figure 2) might con-
stitute the base for future randomized trials investigating the
role of surgery in treating patients with preoperatively dem-
onstrated N2 NSCLC.
Regarding the optimal treatment options for patients with
clinical N2 NSCLC, most authors have argued that these
patients should not undergo surgery.7,9,10,23 Goldstraw and
associates4 thoroughly summarized the conflicting results
of long-term survival associated with surgery in patients
with N2 NSCLC. Surgical series have reported 5-year sur-
vivals from 6% to 35%.1,24 Such range reflects the inclusion
of subsets of patients with N2 disease with different progno-
ses, and also differences in complete resection rates. We
have confirmed that complete resection is a basic require-
ment for long-term survival and that surgery is justified
only if a R0 resection can be achieved. CT scan does not pro-
vide definite landmarks for distinguishing between operable
and inoperable preoperatively diagnosed N2 NSCLC. When
only obvious cases were denied surgery, an incomplete
resection rate as high as 40%was reported.25 The high com-
plete resection rate that we observed (79%) reflects our
selective attitude in cases of positive mediastinoscopy and
confirms that mediastinoscopy as a staging method is supe-
rior to CT scan for prevention of incomplete resections.
The new generation of multiplanar multidetector CT scan
will probably help in predicting a complete resection.
At present, the role of induction chemotherapy in N2
NSCLC remains debated.26-30 Our multivariate analysis in-
dicates that among preoperative prognostic factors induction
chemotherapy and the selection that occurs on the basis of
therapeutic response is a significant predictor of better prog-
nosis. In spite of the striking difference in survival between
patients who underwent preoperative chemotherapy and
those who underwent primary surgery, however, we cannot
conclude that induction chemotherapy is effective in pro-
longing survival, because the percentage of patients who
did not undergo surgery after preoperative chemotherapy
was as high as 45.7%. Since the inclusion of PET scan in
the preoperative staging protocol coincided approximately
with the use of induction chemotherapy, one might argue
that the apparent survival advantage in the induction therapy
group was due to better screening for distant metastases. The
percentage of patients who did not undergo surgery exclu-
sively on the basis of PET scan detection of distant metasta-
ses, however, was less than 2%. This percentage is lower
than others reported in the literature, possibly because of
our extensive preoperative staging and because a single dis-
tant metastasis detected by PET scan was considered a con-
traindication to surgery only if confirmed by histologic or
other diagnostic tests. Because of the very small number
of patients excluded from the study as a result of the preop-
erative use of PET scan, we can conclude that inductiongery c October 2009
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Schemotherapy acts as an effective tool for selecting patients
for resection, helping to identify a subset of patients with
improved prognosis.
The presence of residual N2 disease after induction ther-
apy has been considered a contraindication to surgery.
Bueno and associates31 reported 5-year survivals of 36%
among 29 patients with downstaging to N0 and 9% among
the 74 patients with residual N1 or N2 disease. Similar con-
clusions have been drawn by Voltolini and coworkers,32
Okada and associates,17 and Betticher and colleagues.33 In
the SWOG trial 880534 nodal downstaging was the only in-
dependent favorable prognostic factor identified in a multi-
variate model. Sawabata and colleagues35 investigated the
influence on long-term survival of the number of mediastinal
node levels with residual disease after induction chemother-
apy. Five-year survival was significantly better in 18 patients
(54%) with residual disease at a single N2 level than in 25
patients (11%) with multiple N2 level disease. In our series,
the 5-year survival among 30 patients who had a complete
response in the mediastinum was 69% (95% confidence in-
terval 50%–88%), suggesting that nodal downstaging is as-
sociated with a better prognosis. Furthermore, we confirmed
that the number of metastatic mediastinal nodes after induc-
tion chemotherapy is a significant prognostic factor. In our
study, the response to induction chemotherapy was assessed
by CT scan and PET scan, with remediastinoscopy never
used. In a recent prospective study, De Leyn and col-
leagues36 demonstrated that remediastinoscopy was techni-
cally feasibly; however, the sensitivity and negative
predictive value of remediastinoscopy were low because
of fibrosis. PET scan proved to be more accurate than reme-
diastinoscopy in the restaging of the mediastinum, with
a very high positive predictive value. Because of the signif-
icant prognostic value of residual N2 disease at multiple
levels after induction chemotherapy and the low accuracy
of remediastinoscopy, we are now evaluating an alternative
approach. When a preoperative PET scan shows a positive
result in the mediastinum, an effort is made to obtain N2
demonstration by means of less invasive techniques than
mediastinoscopy (such as transbronchial needle aspiration).
Mediastinoscopy is used after induction chemotherapy to as-
sess resectability to exclude residual tumor in multiple medi-
astinal node levels and to detect unsuspected N3 disease or
paratracheal node metastases in left-sided NSCLC.
CONCLUSIONS
Because the prognosis after resection of patients with clin-
ical N2 NSCLC is generally poor, there is a need for preoper-
ative selection of subgroups of patients who may benefit from
surgery. Although the design of this study does not allow in-
ferences on the relative values of different staging protocols or
treatment strategies, it does provide information on the prog-
noses of different subgroups of patients undergoing surgery
for N2 NSCLC on the basis of significant preoperativeThe Journal of Thoracic and Cprognostic factors. Although our study points out the useful-
ness of the significant postoperative factors for assessing pa-
tient prognosis, the value of these factors for planning
adjuvant treatments remains to be evaluated. Patients with
the favorable prognostic factors we have identified, whether
preoperative or postoperative, have good long-term survivals
(30% and 48% at 5 years, respectively) and excellent local
disease control (73% and 89%, respectively). Thus for these
favorable subsets of patients with N2 NSCLC, surgery should
still be included in the multimodality treatment until other
therapeutic options have been demonstrated to guarantee better
local disease control and long-term survival. Although our
postoperative model proved to absorb all the preoperative prog-
nostic factors, the preoperative model should be maintained as
a useful tool for selecting among candidates for resection those
patients who may have a better prognosis after surgery.
We thank Herbert Dal Corso for his help in preparing the
manuscript.
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